Company intelligence / Profile preview

Kaneka Eurogentec

Seraing, Liège Province, Belgiumeurogentec.com ↗

Ownership: Public · KANKF
Employees: ~350
Development stage: Commercial

Overview

Kaneka Eurogentec provides GMP-certified manufacturing of plasmid DNA, mRNA, recombinant proteins, oligonucleotides, peptides and antibody fragments for research through commercial use. They have expanded capacity for large-scale mRNA production suitable for late-stage clinical trials and commercial supply. The company does not develop its own drug pipeline but enables client programs across multiple modalities.

Therapeutic areas: OncologyRare DiseasesInfectious Diseases
Modalities: Plasmid DNAmRNA therapeuticsRecombinant proteinsOligonucleotides (DNA/RNA)Peptides and complex-modified peptides
Industry: Contract Manufacturing Organization

Partnerships

CepheidEpoch BiosciencesExiqonDelphi GeneticsIn Cell Art

Financials

Market cap: $1.8B
Total revenue: $5.2B
Enterprise value: $2.9B

Beyond the preview

Go deeper on Kaneka Eurogentec.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Kaneka Eurogentec.